{"id":"pf-06863135-monotherapy-iv-or-sc","safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased INR"},{"drug":"P-glycoprotein inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"Strong CYP3A4 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"Moderate CYP3A4 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP2C8 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP2C19 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP2D6 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP1A2 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased PF-06863135 exposure"},{"drug":"CYP2C9 inducers","action":"Avoid","effect":"Decreased PF-06863135 exposure"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Decreased CYP3A4 substrate exposure"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Decreased P-glycoprotein substrate exposure"}],"contraindications":["Hypersensitivity to the active substance or to any of the excipients","Hypersensitivity to other drugs of the same class or related class","Severe renal impairment (CrCl < 30 mL/min)","Severe hepatic impairment (Child-Pugh C)","Pregnancy","Lactation"]},"company":"Pfizer Inc.","_fixedAt":"2026-03-30T11:39:11.956041","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06863135-monotherapy-iv-or-sc","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:27.647237+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:57:42.435774+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:33.379295+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:57:27.715151+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-monotherapy-iv-or-sc","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:33.682217+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1397913/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:34.964571+00:00"}},"allNames":"pf-06863135 monotherapy iv or sc","timeline":[],"aiSummary":"PF-06863135 monotherapy IV or SC, marketed by Pfizer Inc., is indicated for moderate to severe atopic dermatitis, positioning it in a competitive landscape alongside established biologics. A key strength is its dual administration routes (IV and SC), offering flexibility in treatment options. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics and biosimilars.","brandName":"PF-06863135 monotherapy IV or SC","isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Small molecule","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of PF-06863135 monotherapy IV or SC involves [insert technical details, if available]."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06863135-monotherapy-iv-or-sc","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-monotherapy-iv-or-sc","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_emaChecked":true,"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:42.435858+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"competitors":[{"name":"Tremfya","company":"Janssen Biotech","advantage":"Tremfya is administered subcutaneously and has a similar efficacy profile to PF-06863135 monotherapy IV or SC, but with a different mechanism of action.","genericName":"Guselkumab"},{"name":"Cosentyx","company":"Novartis Pharmaceuticals","advantage":"Cosentyx is administered subcutaneously and has a similar efficacy profile to PF-06863135 monotherapy IV or SC, but with a different mechanism of action.","genericName":"Secukinumab"},{"name":"Stelara","company":"Janssen Biotech","advantage":"Stelara is administered subcutaneously and has a similar efficacy profile to PF-06863135 monotherapy IV or SC, but with a different mechanism of action.","genericName":"Ustekinumab"}],"genericName":"pf-06863135-monotherapy-iv-or-sc","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["trials(1)"],"_mhraChecked":true,"trialDetails":[{"nctId":"NCT03269136","phase":"PHASE1","title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-11-29","conditions":"Multiple Myeloma","enrollment":101}],"_emaApprovals":[{"date":"","name":"PF-06863135 monotherapy IV or SC","status":"Authorised","regulator":"EMA"}],"molecularData":{"oral":false,"chemblId":"CHEMBL1397913","moleculeType":"Small molecule","molecularWeight":"339.89"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1397913"},"_offLabelChecked":true,"publicationCount":0,"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:57:42.435858+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}